ABOUT US

Who We Are

Samsung Bioepis reimagines and redefines the way medicines are made.

We make high quality biologic medicines more accessible, more quickly

Samsung Bioepis is a biopharmaceutical company dedicated to unlocking the potential of biosimilar medicines and transforming the way
biologic therapies are brought to patients. Our mission is reflected in our name, bio-epis; literally meaning life (“bio”) and science (“episteme”) in Greek.
We want to enhance the lives of patients through our pioneering and innovative use of science and technology.

Our approach

We are a young company, challenging traditional approaches and harnessing new technologies to find smarter, faster ways of getting high-quality medicines to the people who need them.

Our partners

We work hand in hand with other carefully chosen partners to commercialize our products around the world and ensure supply and access for the people who need them. Our partners include Biogen, MSD.

Our achievements

In the eight years since our company was founded, we have developed one of the most expansive and rapidly growing biosimilars portfolios in the industry. We have already opened up access to life-changing and life-saving medicines in immunology and oncology, including being the first to secure European approval of three key biosimilars for autoimmune conditions. We were the first company to gain European approval for trastuzumab biosimilar in certain types of breast cancer and metastatic gastric cancer. Also, We received European approval for bevacizumab biosimilar in certain types of metastatic carcinoma of the colon or rectum (mCRC), non-small cell lung cancer (NSCLC) and currently bevacizumab biosimilar is under consideration by the FDA.

Our future

As long as patients face barriers to accessing the medicines they need, we will continue to strive for constant innovation. We are expanding into new areas of unmet need in ophthalmology, hematology, and gastroenterology. We are also harnessing our smart development process for biosimilars to develop the next generation of novel biologics. Our work has only just begun.

Corporate Brochure DOWNLOAD

Since our launch in 2012, we have developed the industry’s most rapidly advancing biosimilar medicines portfolio and have become a leader in biosimilars.

2012
  • Samsung Bioepis is established
  • Samsung Bioepis opens
    R&D Center
2013
  • Partnership with Merck&Co.
    (also known as MSD)
  • Partnership with Biogen
2015
  • 2 biosimilars (infliximab and
    etanercept) approved by MFDS
    (Korea)
2016
  • 2 biosimilars (infliximab and
    etanercept) approved by EC
    (Europe)
2017
  • 1 biosimilar (infliximab)
    approved by FDA (US)
  • 2 biosimilars (adalimumab and
    trastuzumab) approved by EC
    (Europe)
  • Partnership with Takeda
  • 2 biosimilars (adalimumab and
    trastuzumab) approved by MFDS
    (Korea)
  • 1 biosimilar (etanercept) approved
    by ANVISA (Brazil)
2018
  • 1 biosimilar (infliximab)
    approved by ANVISA (Brazil)
2019
  • Partnership with 3SBio
  • Partnership with C-bridge
    Capital
  • 3 biosimilars (trastuzumab, etanercept and adalimumab) approved by FDA (US)
2020
  • 1 biosimilar (bevacizumab)
    approved by EC (Europe)
Corporate Brochure DOWNLOAD